Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1983 2
1984 1
1985 1
1987 2
1988 5
1989 1
1990 2
1991 2
1993 1
1994 2
1995 9
1996 8
1997 5
1998 5
1999 5
2000 4
2001 10
2002 7
2003 12
2004 9
2005 12
2006 14
2007 8
2008 14
2009 13
2010 6
2011 5
2012 10
2013 8
2014 10
2015 8
2016 6
2017 8
2018 4
2019 6
2020 1
2021 9
2022 16
2023 10
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Morris WJ, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24. Int J Radiat Oncol Biol Phys. 2017. PMID: 28262473 Clinical Trial.
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Rodda S, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6. Int J Radiat Oncol Biol Phys. 2017. PMID: 28433432 Clinical Trial.
An Updated Analysis of the Survival Endpoints of ASCENDE-RT.
Oh J, Tyldesley S, Pai H, McKenzie M, Halperin R, Duncan G, Morton G, Keyes M, Hamm J, Morris WJ. Oh J, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1061-1070. doi: 10.1016/j.ijrobp.2022.11.005. Epub 2022 Dec 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 36528488 Clinical Trial.
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Sholler GLS, et al. Among authors: halperin rf. Genome Med. 2024 Feb 12;16(1):28. doi: 10.1186/s13073-024-01297-5. Genome Med. 2024. PMID: 38347552 Free PMC article. Clinical Trial.
Germline CDKN1B variant type and site are associated with phenotype in MEN4.
Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A, Friedman E, Bernstein-Molho R, Tirosh A. Halperin R, et al. Endocr Relat Cancer. 2022 Dec 12;30(1):e220174. doi: 10.1530/ERC-22-0174. Print 2023 Jan 1. Endocr Relat Cancer. 2022. PMID: 36256846 Review.
Improved methods for RNAseq-based alternative splicing analysis.
Halperin RF, Hegde A, Lang JD, Raupach EA; C4RCD Research Group; Legendre C, Liang WS, LoRusso PM, Sekulic A, Sosman JA, Trent JM, Rangasamy S, Pirrotte P, Schork NJ. Halperin RF, et al. Sci Rep. 2021 May 24;11(1):10740. doi: 10.1038/s41598-021-89938-2. Sci Rep. 2021. PMID: 34031440 Free PMC article.
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.
Anker J, Pal SK, Kim-Schulze S, Wang H, Halperin R, Uzilov A, Imai N, Eikawa S, Saito T, Sebra R, Hahn NM, Patel M, Qi J, Xie H, Bhardwaj N, Gnjatic S, Galsky MD. Anker J, et al. Among authors: halperin r. J Immunother Cancer. 2023 Aug;11(8):e007613. doi: 10.1136/jitc-2023-007613. J Immunother Cancer. 2023. PMID: 37607770 Free PMC article.
A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
Crook J, Moideen N, Arbour G, Castro F, Araujo C, Batchelar D, Halperin R, Hilts M, Kim D, Petrik D, Rose J, Cheng JC, Bachand F. Crook J, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):59-68. doi: 10.1016/j.ijrobp.2024.02.064. Epub 2024 Mar 16. Int J Radiat Oncol Biol Phys. 2024. PMID: 38493901 Free article. Clinical Trial.
240 results